`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`Filed on behalf of Patent Owner Genentech, Inc. by:
`
`David L. Cavanaugh
`Reg. No. 36,476
`Owen K. Allen
`Reg. No. 71,118
`Robert J. Gunther, Jr.
`Pro Hac Vice Pending
`Wilmer Cutler Pickering
`Hale and Dorr LLP
`1875 Pennsylvania Ave., NW
`Washington, DC 20006
`
`
`Adam R. Brausa
`Reg. No. 60,287
`Daralyn J. Durie
`Pro Hac Vice Pending
`Durie Tangri LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner.
`____________________________________________
`
`Cases IPR2016-01694
`Patent 6,407,213
`____________________________________________
`
`
`PATENT OWNER’S UNOPPOSED MOTION FOR ADMISSION
`PRO HAC VICE OF ROBERT J. GUNTHER, JR.
`
`
`
`
`- 1 -
`
`
`
`Case No. IPR2016-01694
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`I. Statement of Precise Relief Requested
`
`Pursuant to 37 C.F.R. § 42.10(c), Patent Owner Genentech, Inc.
`
`(“Genentech”) requests that the Patent Trial and Appeal Board (the “Board”) admit
`
`Robert J. Gunther, Jr. pro hac vice in this proceeding, IPR2016-01694. Petitioner
`
`Mylan Pharmaceuticals Inc. has indicated that it does not oppose this motion.
`
`II. Statement of Facts Showing Good Cause for the Board to Recognize
`Counsel Pro Hac Vice During the Proceeding
`In accordance with 37 C.F.R. § 42.10(c), the Board may recognize counsel
`
`pro hac vice during a proceeding upon a showing of good cause, subject to the
`
`condition that lead counsel be a registered practitioner and to any other conditions
`
`as the Board may impose. Section 42.10(c) indicates that “where lead counsel is a
`
`registered practitioner, a motion to appear pro hac vice by counsel who is not a
`
`registered practitioner may be granted upon a showing that counsel is an
`
`experienced litigating attorney and has an established familiarity with the subject
`
`matter at issue in the proceeding.” The facts here establish good cause for the
`
`Board to recognize Robert J. Gunther, Jr. pro hac vice in this proceeding.
`
`1. Lead counsel, David L. Cavanaugh, is a registered practitioner. Backup
`
`counsel, Owen K. Allen and Adam R. Brausa, are also registered
`
`practitioners.
`
`
`
`- 2 -
`
`
`
`Case No. IPR2016-01694
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`2. Counsel, Robert J. Gunther, Jr., is an experienced litigator and has an
`
`established familiarity with the subject matter at issue in the proceeding.
`
`Accompanying this motion as Exhibit 2032 is the Declaration of Robert J.
`
`Gunther, Jr. in Support of this Motion for Admission Pro Hac Vice
`
`(“Gunther Decl.”). In his declaration, Mr. Gunther asserts:
`
`I am a member in good standing of the Bar of New York, and
`am admitted to practice before District Courts of the Southern
`District of New York the Eastern District of New York, the
`Western District of New York, the Northern District of
`California, the District of Colorado, the Eastern District of
`Michigan, the Western District of Michigan, and the Northern
`District of Illinois. I am also admitted to practice before the
`U.S. Courts of Appeals for the Second, Ninth, Tenth, and
`Federal Circuits. I am a fellow of The American College of
`Trial Lawyers.
`
`Gunther Decl. ¶ 2 (Ex. 2032). Mr. Gunther also states that he has a long-
`
`standing relationship with Patent Owner Genentech, Inc. and its parent
`
`Roche. Gunther Decl. ¶ 11 (Ex. 2032). Mr. Gunther also demonstrates that
`
`he has a detailed working knowledge of the relevant subject matter through
`
`his participation as counsel in prior and concurrent antibody-related patent
`
`cases. Gunther Decl. ¶ 12 (Ex. 2032).
`
`
`
`- 3 -
`
`
`
`Case No. IPR2016-01694
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`3. In his declaration, Mr. Gunther also attests to each of the listed items
`
`required by the Order – Authorizing Motion for Pro Hac Vice Admission –
`
`37 C.F.R. § 42.10 in IPR2013-00639. See Gunther Decl. ¶¶ 1-13 (Ex.
`
`2032). Mr. Gunther attests that he has read and will comply with the Office
`
`Patent Trial Practice Guide and the Board’s Rules of Practice for Trials set
`
`forth in 37 C.F.R. § 42. See id. ¶ 8. Mr. Gunther further attests that he
`
`agrees to be subject to the United States Patent and Trademark Office’s
`
`Rules of Professional Conduct as set forth in 37 C.F.R. §§ 11.101 et seq. and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a). See id. ¶ 9.
`
`III. Conclusion
`
`For the foregoing reasons, Patent Owner respectfully requests that the Board
`
`admit Robert J. Gunther, Jr. pro hac vice in this proceeding.
`
`
`
`Date: December 29, 2016
`
`Respectfully submitted,
`
`By: /David L. Cavanaugh/
`David L. Cavanaugh
`Reg. No. 36,476
`Wilmer Cutler Pickering Hale and Dorr LLP
`1875 Pennsylvania Avenue NW
`Washington, DC 20006
`
`
`
`- 4 -
`
`
`
`Case No. IPR2016-01694
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`PATENT OWNER’S EXHIBIT LIST
`IPR2016-01694
`Exhibit Name
`
`Patent Owner’s
`Exhibit Number
`2001
`
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Genentech, Inc. Laboratory Notebook No. 10098 (Leonard
`Presta)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 10823 (Leonard
`Presta)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 11268 (Paul Carter)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 11643 (Paul Carter)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 10840 (John Brady)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 11162 (John Brady)
`PROTECTIVE ORDER MATERIAL
`Excerpts from Genentech, Inc. Laboratory Notebook No. 11008
`(Ann Rowland)
`PROTECTIVE ORDER MATERIAL
`Excerpts from Genentech, Inc. Laboratory Notebook No. 11297
`(Tim Hotaling)
`PROTECTIVE ORDER MATERIAL
`Excerpts from Genentech, Inc. Laboratory Notebook No. 11568
`(Monique Carver)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Interoffice Memorandum from Paul Carter to
`Leonard Presta and Dennis Henner
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Interoffice Memorandum from Paul Carter to
`Leonard Presta
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Synthetic DNA Requests
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Synthetic DNA Requests
`PROTECTIVE ORDER MATERIAL
`
`
`
`- i -
`
`
`
`Case No. IPR2016-01694
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`Exhibit Name
`
`Patent Owner’s
`Exhibit Number
`2014
`
`
`Genentech, Inc. Protein Engineering of 4D5 Status Report
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Interoffice Memorandum re: RCC Minutes and
`Recommendations
`PROTECTIVE ORDER MATERIAL
`Declaration of Irene Loeffler
`Modified Default Standing Protective Order – Redline
`Declaration of John Ridgway Brady
`PROTECTIVE ORDER MATERIAL
`Paul Carter, et al., Humanization of the Anti-p185 Antibody for
`Human Cancer Therapy, 89 PROC. NATL. ACAD. SCI. 4285-
`4289 (1992)
`Leonard Presta, et al., Humanization of an Anti-Vascular
`Endothelial Growth Factor Monoclonal Antibody for the
`Therapy of Solid Tumors and Other Disorders, 57 CANCER
`RESEARCH 4593-4599 (1997)
`Marianne Bruggerman, et al., The Immunogenicity of Chimeric
`Antibodies, 170 J. EXP. MED. 2153-2157 (1989)
`Jatinderpal Kalsi, et al., Structure-function Analysis and the
`Molecular Origins of Anti-DNA Antibodies in Systemic Lupus
`Erythematosus, EXPERT REVIEWS IN MOLECULAR MEDICINE 1-
`28 (1999)
`Scott Gorman, et al., Reshaping a Therapeutic CD4 Antibody,
`88 PROC. NATL. ACAD. SCI. 4181-4185 (1991)
`John Isaacs, et al., Humanised Monoclonal Antibody Therapy
`for Rheumatoid Arthritis, 340 THE LANCET 748-752 (1992)
`Elvin Kabat, et al., Sequences of Proteins of Immunological
`Interest 1-23 (4th ed. 1987)
`Anna Tramontano, et al., Framework Residue 71 Is a Major
`Determinant of the Position and Conformation of the Second
`Hypervariable Region in the VH Domains of Immunoglobulins,
`215 J. MOL. BIOL. 175-182 (1990)
`H.M. SHEPARD, et al., Herceptin, in Therapeutic Antibodies.
`HANDBOOK OF EXPERIMENTAL PHARMACOLOGY 183-219 (Y.
`Chernajovsky & A. Nissim, eds. 2008)
`Excerpt from Roche Finance Report 2015
`
`2015
`
`2016
`2017
`2018
`
`2019
`
`2020
`
`2021
`
`2022
`
`2023
`
`2024
`
`2025
`
`2026
`
`2027
`
`2028
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`- ii -
`
`
`
`Case No. IPR2016-01694
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`Exhibit Name
`
`Patent Owner’s
`Exhibit Number
`2029
`
`
`2030
`
`2031
`
`2032
`
`2033
`
`
`
`
`
`
`
`
`
`Declaration of Dr. Leonard G. Presta
`PROTECTIVE ORDER MATERIAL
`Declaration of Dr. Paul J. Carter
`PROTECTIVE ORDER MATERIAL
`Modified Default Standing Protective Order and Patent
`Owner’s Certification of Agreement to Terms
`Declaration of Robert J. Gunther, Jr. in Support of Motion for
`Admission Pro Hac Vice
`Declaration of Daralyn J. Durie in Support of Motion for
`Admission Pro Hac Vice
`
`
`
`
`
`
`
`- iii -
`
`
`
`Case No. IPR2016-01694
`Patent Owner’s Motion For Admission Pro Hac Vice Of Robert J. Gunther, Jr.
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that, on December 29, 2016, I caused a true and correct copy
`of the following materials:
`
`
`
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of
`Robert J. Gunther, Jr.
` Exhibit 2032
` Patent Owner’s Exhibit List
`
`to be served via electronic mail on the following attorneys of record:
`
`Jeffrey W. Guise
`WILSON SONSINI GOODRICH & ROSATI
`650 Page Mill Road
`Palo Alto, CA 94304
`jguise@wsgr.com
`
`Deanne M. Mazzochi
`RAKOCZY MOLINO MAZZOCHI SIWIK LLP
`6 West Hubbard Street, Suite 500
`Chicago, IL 60654
`dmazzochi@rmmslegal.com
`
`
`/Owen K. Allen/
`Owen K. Allen
`Reg. No. 71,118
`Wilmer Cutler Pickering Hale and Dorr LLP
`950 Page Mill Road
`Palo Alto, CA 94304
`(650) 600-5029
`
`
`
`ActiveUS 160221966v.1
`
`- iv -